SlideShare uma empresa Scribd logo
1 de 17
[object Object],[object Object],[object Object],STRICTLY CONFIDENTIAL
STRICTLY CONFIDENTIAL This presentation has been issued in connection with a proposed placing (the “Placing”) of new ordinary shares in AntNano plc   (the “Company”).  The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice.  No assurance is given by the Company that any ordinary shares of the Company will be sold in the Placing.  This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or any other document or oral statement, or on the completeness, accuracy or fairness of such information and/or opinions therein. No representation or warranty, express or implied, is made or given by or on behalf of the Company, any of their respective directors, or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for such information or opinions or for any errors, omissions, misstatements, negligent or otherwise, or for any communication written or otherwise, contained or referred to in this presentation. DISCLAIMER
STRICTLY CONFIDENTIAL Accordingly, neither the Company nor any of their respective directors, officers, employees, advisers, associated persons or subsidiary undertakings shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon the statement or as a result of any admission in, or any document supplied with, this presentation or by any future communications in connection with such documents and any such liabilities are expressly disclaimed. Prospective investors interested in investing in the Company are recommended to seek their own independent financial advice from a person authorised for the purposes of the Financial Services and Markets Act 2000. This presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person. This presentation is not for distribution outside the United Kingdom and, in particular, should not be distributed to persons with addresses in Canada, Australia, Japan, Republic of Ireland, Republic of South Africa, or to persons with addresses in the United States of America, its territories or possession or to any  citizen thereof or to any corporation, partnership or other entity created or organized under the laws thereof. Any such distribution could result in the violation of  Canadian, Australian, Japanese, Irish, South African or United States of America law. The information in this presentation is confidential and must not be copied, reproduced or distributed to others at any time except for the purposes of analysis by certain employees and advisers of the recipient who have agreed to be bound by the restrictions contained herein.   DISCLAIMER (cont.)
STRICTLY CONFIDENTIAL ,[object Object],[object Object],[object Object],[object Object],Market Pull; Not Tech Push
STRICTLY CONFIDENTIAL The Economic Argument Time Hrs Amortised Cost/test  £ Existing Galley Sampler >150 64 New AntNano Dip Strips 4 30 AntNano Real Time Analyser 0.1 1.5
Real Time Air Analyser ,[object Object],[object Object],[object Object],[object Object],[object Object],STRICTLY CONFIDENTIAL Cyclone Bioreactor Fluorimeter Fluid In Air In Air Out Waste
STRICTLY CONFIDENTIAL High Volume Air Sampling Real Time Measurement Monitoring of Airborne Enzymes Current Product Range
STRICTLY CONFIDENTIAL Route to Market   ,[object Object],[object Object],[object Object],[object Object]
STRICTLY CONFIDENTIAL Customers   ,[object Object],[object Object],[object Object],[object Object],[object Object],Industrial  (Enzyme  Detection) Oestrogen Steroid Detection   Dioxin  Detection Infectious  Disease  Detection   Counter  Terrorism ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STRICTLY CONFIDENTIAL Sustainable Advantages ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Security Applications
ANT Explosive Approach
[object Object],[object Object],[object Object],[object Object],[object Object],STRICTLY CONFIDENTIAL Management
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],STRICTLY CONFIDENTIAL Management
STRICTLY CONFIDENTIAL Financial Summary
STRICTLY CONFIDENTIAL Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STRICTLY CONFIDENTIAL ,[object Object],[object Object],[object Object],[object Object],[object Object],Investment Opportunity

Mais conteúdo relacionado

Semelhante a Ant Nano presentation to CONNECT North East Conference 09

Sienna corporate presentation 29 may2017
Sienna corporate presentation 29 may2017Sienna corporate presentation 29 may2017
Sienna corporate presentation 29 may2017Reach Markets
 
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013ANGLE plc
 
ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13ANGLE plc
 
Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015ANGLE plc
 
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
 
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum ANGLE plc
 
ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015ANGLE plc
 
Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum  Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum ANGLE plc
 
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
Tiziana Life Sciences (NASDAQ: TLSA) Investor PresentationTiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
Tiziana Life Sciences (NASDAQ: TLSA) Investor PresentationRedChip Companies, Inc.
 
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020RedChip Companies, Inc.
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCovance
 
Johnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business ReviewJohnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
 
Quintain Consulting Presentation
Quintain Consulting PresentationQuintain Consulting Presentation
Quintain Consulting Presentationjeanettepritchard
 
AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AnitaBell
 
Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014ANGLE plc
 

Semelhante a Ant Nano presentation to CONNECT North East Conference 09 (20)

ieCrowd Pesentation
ieCrowd PesentationieCrowd Pesentation
ieCrowd Pesentation
 
Sienna corporate presentation 29 may2017
Sienna corporate presentation 29 may2017Sienna corporate presentation 29 may2017
Sienna corporate presentation 29 may2017
 
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
 
ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13
 
TLSA Investor Presentation August 2021
TLSA Investor Presentation August 2021TLSA Investor Presentation August 2021
TLSA Investor Presentation August 2021
 
Imugene Limited - ASX: IMU
Imugene Limited - ASX: IMUImugene Limited - ASX: IMU
Imugene Limited - ASX: IMU
 
Imugene Corporate Presentation
Imugene Corporate PresentationImugene Corporate Presentation
Imugene Corporate Presentation
 
Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015
 
TLSA Investor Presentation October 2021
TLSA Investor Presentation October 2021TLSA Investor Presentation October 2021
TLSA Investor Presentation October 2021
 
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
 
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
 
ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015
 
Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum  Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum
 
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
Tiziana Life Sciences (NASDAQ: TLSA) Investor PresentationTiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
 
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020
 
Cell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval SolutionsCell & Gene Therapy Post-Approval Solutions
Cell & Gene Therapy Post-Approval Solutions
 
Johnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business ReviewJohnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business Review
 
Quintain Consulting Presentation
Quintain Consulting PresentationQuintain Consulting Presentation
Quintain Consulting Presentation
 
AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101
 
Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014
 

Último

Cyber Security Training in Office Environment
Cyber Security Training in Office EnvironmentCyber Security Training in Office Environment
Cyber Security Training in Office Environmentelijahj01012
 
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdfChris Skinner
 
Church Building Grants To Assist With New Construction, Additions, And Restor...
Church Building Grants To Assist With New Construction, Additions, And Restor...Church Building Grants To Assist With New Construction, Additions, And Restor...
Church Building Grants To Assist With New Construction, Additions, And Restor...Americas Got Grants
 
Healthcare Feb. & Mar. Healthcare Newsletter
Healthcare Feb. & Mar. Healthcare NewsletterHealthcare Feb. & Mar. Healthcare Newsletter
Healthcare Feb. & Mar. Healthcare NewsletterJamesConcepcion7
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxmbikashkanyari
 
Effective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold JewelryEffective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold JewelryWhittensFineJewelry1
 
Supercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebsSupercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebsGOKUL JS
 
Technical Leaders - Working with the Management Team
Technical Leaders - Working with the Management TeamTechnical Leaders - Working with the Management Team
Technical Leaders - Working with the Management TeamArik Fletcher
 
NAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors DataNAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors DataExhibitors Data
 
Send Files | Sendbig.comSend Files | Sendbig.com
Send Files | Sendbig.comSend Files | Sendbig.comSend Files | Sendbig.comSend Files | Sendbig.com
Send Files | Sendbig.comSend Files | Sendbig.comSendBig4
 
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdftrending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdfMintel Group
 
Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...
Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...
Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...ssuserf63bd7
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
Excvation Safety for safety officers reference
Excvation Safety for safety officers referenceExcvation Safety for safety officers reference
Excvation Safety for safety officers referencessuser2c065e
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationAnamaria Contreras
 
Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...Peter Ward
 
APRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdfAPRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdfRbc Rbcua
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024Adnet Communications
 

Último (20)

Cyber Security Training in Office Environment
Cyber Security Training in Office EnvironmentCyber Security Training in Office Environment
Cyber Security Training in Office Environment
 
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
 
Church Building Grants To Assist With New Construction, Additions, And Restor...
Church Building Grants To Assist With New Construction, Additions, And Restor...Church Building Grants To Assist With New Construction, Additions, And Restor...
Church Building Grants To Assist With New Construction, Additions, And Restor...
 
Healthcare Feb. & Mar. Healthcare Newsletter
Healthcare Feb. & Mar. Healthcare NewsletterHealthcare Feb. & Mar. Healthcare Newsletter
Healthcare Feb. & Mar. Healthcare Newsletter
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
 
Effective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold JewelryEffective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold Jewelry
 
Supercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebsSupercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebs
 
Technical Leaders - Working with the Management Team
Technical Leaders - Working with the Management TeamTechnical Leaders - Working with the Management Team
Technical Leaders - Working with the Management Team
 
NAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors DataNAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors Data
 
Send Files | Sendbig.comSend Files | Sendbig.com
Send Files | Sendbig.comSend Files | Sendbig.comSend Files | Sendbig.comSend Files | Sendbig.com
Send Files | Sendbig.comSend Files | Sendbig.com
 
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdftrending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
 
Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...
Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...
Horngren’s Financial & Managerial Accounting, 7th edition by Miller-Nobles so...
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
Excvation Safety for safety officers reference
Excvation Safety for safety officers referenceExcvation Safety for safety officers reference
Excvation Safety for safety officers reference
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
 
Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...
 
APRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdfAPRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdf
 
WAM Corporate Presentation April 12 2024.pdf
WAM Corporate Presentation April 12 2024.pdfWAM Corporate Presentation April 12 2024.pdf
WAM Corporate Presentation April 12 2024.pdf
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024
 
The Bizz Quiz-E-Summit-E-Cell-IITPatna.pptx
The Bizz Quiz-E-Summit-E-Cell-IITPatna.pptxThe Bizz Quiz-E-Summit-E-Cell-IITPatna.pptx
The Bizz Quiz-E-Summit-E-Cell-IITPatna.pptx
 

Ant Nano presentation to CONNECT North East Conference 09

  • 1.
  • 2. STRICTLY CONFIDENTIAL This presentation has been issued in connection with a proposed placing (the “Placing”) of new ordinary shares in AntNano plc (the “Company”). The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice. No assurance is given by the Company that any ordinary shares of the Company will be sold in the Placing. This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or any other document or oral statement, or on the completeness, accuracy or fairness of such information and/or opinions therein. No representation or warranty, express or implied, is made or given by or on behalf of the Company, any of their respective directors, or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for such information or opinions or for any errors, omissions, misstatements, negligent or otherwise, or for any communication written or otherwise, contained or referred to in this presentation. DISCLAIMER
  • 3. STRICTLY CONFIDENTIAL Accordingly, neither the Company nor any of their respective directors, officers, employees, advisers, associated persons or subsidiary undertakings shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon the statement or as a result of any admission in, or any document supplied with, this presentation or by any future communications in connection with such documents and any such liabilities are expressly disclaimed. Prospective investors interested in investing in the Company are recommended to seek their own independent financial advice from a person authorised for the purposes of the Financial Services and Markets Act 2000. This presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person. This presentation is not for distribution outside the United Kingdom and, in particular, should not be distributed to persons with addresses in Canada, Australia, Japan, Republic of Ireland, Republic of South Africa, or to persons with addresses in the United States of America, its territories or possession or to any citizen thereof or to any corporation, partnership or other entity created or organized under the laws thereof. Any such distribution could result in the violation of Canadian, Australian, Japanese, Irish, South African or United States of America law. The information in this presentation is confidential and must not be copied, reproduced or distributed to others at any time except for the purposes of analysis by certain employees and advisers of the recipient who have agreed to be bound by the restrictions contained herein. DISCLAIMER (cont.)
  • 4.
  • 5. STRICTLY CONFIDENTIAL The Economic Argument Time Hrs Amortised Cost/test £ Existing Galley Sampler >150 64 New AntNano Dip Strips 4 30 AntNano Real Time Analyser 0.1 1.5
  • 6.
  • 7. STRICTLY CONFIDENTIAL High Volume Air Sampling Real Time Measurement Monitoring of Airborne Enzymes Current Product Range
  • 8.
  • 9.
  • 10.
  • 11.
  • 13.
  • 14.
  • 16.
  • 17.